Light Mode
$0.0017 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.0017, and at the day’s high of $0.0018
+0.00 (+70.00%) / 6M
Momentum, market sentiment, and recent alerts
HALB reads very good: price sits above both the 20- and 200-day averages, the 12-month move is -5.6%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Halberd Corp. is a development stage company, which engages in the research and development of antibodies and devices for the prevention, detection, and treatment of neurodegenerative diseases. It offers patented extracorporeal treatment that is applicable to various blood-borne and neurologic diseases such as PTSD/ CTE (Post Traumatic Stress Disorder/Chronic Traumatic Encephalopathy), Alzheimer's Disease, and Parkinson's Disease. The company was founded by Mark Sven Lundquist and John Christopher Maddox on January 26, 2009 and is headquartered in Jackson Center, PA.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.